Evidence map›Paper›PMID 39026630›Full record

ArticleRSC medicinal chemistry2024

Leveraging bounded datapoints to classify molecular potency improvements.

Zachary Fralish, Paul Skaluba, Daniel Reker

Abstract read
In one paragraph

Article in RSC medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zachary FralishDepartment of Biomedical Engineering, Duke University Durham NC 27708 USA daniel.reker@duke.edu.ORCID https://orcid.org/0000-0001-6293-1730
Paul SkalubaDepartment of Biomedical Engineering, Duke University Durham NC 27708 USA daniel.reker@duke.edu.
Daniel RekerDepartment of Biomedical Engineering, Duke University Durham NC 27708 USA daniel.reker@duke.edu.ORCID https://orcid.org/0000-0003-4789-7380

Funding

Designing Personalized Formulations with Machine LearningR35GM151255 · NIGMS · DUKE UNIVERSITY · PI Daniel Reker · 2023 to 2026
$1.4M
NIGMS NIH HHS R35 GM151255
6 · The paper itself

Abstract

Molecular machine learning algorithms are becoming increasingly powerful at predicting the potency of potential drug candidates to guide molecular discovery, lead series prioritization, and structural optimization. However, a substantial amount of inhibition data is bounded and inaccessible to traditional regression algorithms. Here, we develop a novel molecular pairing approach to process this data. This creates a new classification task of predicting which one of two paired molecules is more potent. This novel classification task can be accurately solved by various, established molecular machine learning algorithms, including XGBoost and Chemprop. Across 230 ChEMBL IC

Identifiers

PMID39026630
PMCPMC11253865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.